“…However, these findings also raise the question of what signaling pathways and physiological responses are critical for specific in vivo actions of mGlu 5 PAMs. As new tools are further developed that selectively modulate specific signaling pathways by mGlu 5 , they will provide opportunities to develop a full understanding of the specific signaling pathways that are critical for mediating the efficacy of mGlu 5 PAMs in preclinical models of numerous CNS disorders including schizophrenia, fragile X syndrome, Rett syndrome, autistic spectrum disorders, obsessive compulsive disorder, Parkinson's disease, substance abuse (Ade et al, 2016; Gass et al, 2016; Gogliotti et al, 2016; Gould et al, 2016; Michalon et al, 2012; Rylander et al, 2010; Vicidomini et al, 2016), and others.…”